TNFSF13B and rheumatoid arthritis: Novel diagnostic serum and synovial markers such as alpha-defensin, soluble tumor necrosis factor receptor, and B-cell activating factor, as well as technologies such as next-generation sequencing, promise to improve current standards [18,28,29] and could especially benefit rheumatoid arthritis patients.